Evidence map›Paper›PMID 38524646›Full record

ArticleInternational cancer conference journal2024

Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring

Shogo Yamamura, Masashi Kanai, Yasuhide Takeuchi, Natsuko Okita, Tomohiro Kondo, Masahiro Yoshioka, Junichi Matsubara, Shigemi Matsumoto, Manabu Muto

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
4.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. From gene panel testing to new molecularly targeted therapy.International cancer conference journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shogo YamamuraDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.ORCID 0009-0005-4228-3963
Masashi KanaiDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Yasuhide TakeuchiDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Natsuko OkitaClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
Tomohiro KondoDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Masahiro YoshiokaDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Junichi MatsubaraDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Shigemi MatsumotoDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Manabu MutoDepartment of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan.
Kyoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine carcinoma (NEC) of the gallbladder origin is particularly rare, accounting for only 0.38% of primary malignancies of the gallbladder, and standard therapies are limited. The

Indexed as

Capmatinibc-MetGallbladder cancerMANECMET amplificationMET inhibitorMiNENNeuroendocrine carcinomaNeuroendocrine carcinoma of the gallbladder origin

Identifiers

PMID38524646
PMCPMC10957854
OpenAlexW4390512131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.